Novelion Therapeutics Inc. Common Shares
NVLN
NVLN was delisted on the 8th of October, 2019.
82 hedge funds and large institutions have $47.1M invested in Novelion Therapeutics Inc. Common Shares in 2017 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 25 increasing their positions, 12 reducing their positions, and 6 closing their positions.
167% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 6
108% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 12
14% more funds holding
Funds holding: 72 → 82 (+10)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
51% less call options, than puts
Call options by funds: $50K | Put options by funds: $103K
53% less capital invested
Capital invested by funds: $99.3M → $47.1M (-$52.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EIG
EdgePoint Investment Group
Toronto,
Ontario, Canada
|
+$5.54M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.15M |
| 3 |
HVC
Healthcare Value Capital
Woodcliff Lake,
New Jersey
|
+$570K |
| 4 |
State Street
Boston,
Massachusetts
|
+$353K |
| 5 |
Morgan Stanley
New York
|
+$339K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
-$6.03M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$633K |
| 3 |
AA
Ancora Advisors
Cleveland,
Ohio
|
-$558K |
| 4 |
LCS
Levin Capital Strategies
New York
|
-$515K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$225K |
NVLN Hedge Fund Activity: Q4 2017 in Review
82 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Novelion Therapeutics Inc. Common Shares (NVLN) for Q4 2017, worth a combined $47.1M — down 53% from $99.3M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new NVLN positions and 6 closed out — a net gain of 10 holders — while 25 added to existing stakes and 12 trimmed.
The largest buyer was EdgePoint Investment Group, adding an estimated $5.54M. The largest seller was Highbridge Capital Management, exiting entirely with an estimated $6.03M sold.
- 82 institutional investors held Novelion Therapeutics Inc. Common Shares (NVLN) as of Q4 2017, up from 72 in Q3 2017.
- Funds reported $47.1M of Novelion Therapeutics Inc. Common Shares stock for Q4 2017, down 53% quarter-over-quarter.
- 16 funds opened new Novelion Therapeutics Inc. Common Shares positions in Q4 2017 and 6 closed out, a net change of +10 holders.
- The largest Novelion Therapeutics Inc. Common Shares buyer in Q4 2017 was EdgePoint Investment Group, an estimated $5.54M added.
- The largest Novelion Therapeutics Inc. Common Shares seller in Q4 2017 was Highbridge Capital Management, an estimated $6.03M sold.
Based on aggregated 13F filings for Q4 2017.